Theranos

By 2015, Theranos was valued at roughly $9 billion on the promise of a machine that could run hundreds of tests from a single finger-prick of blood. There was one problem: the technology did not work, and Elizabeth Holmes knew it. The company kept promising a product that did not exist, and each time investors, partners, or patients showed up, it found a new way to fake the result rather than admit the gap.

Founders will recognize the trap long before they recognize the fraud. This case sits on the line between a stretch goal and a lie, and it sharpens the hardest judgment call a leader makes: when the honest answer is "this isn't working," but sunk cost, outside pressure, and your own identity all pull the other way. It is less about a villain than about the structural forces that make smart, ambitious people unable to stop. What pulls a company back from that edge is the part worth opening the app for.